Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tiotropium

tiotropium

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of tiotropium

83 trials tracked of tiotropium: 62 in phase 3 or 4 and 10 with published results. The most-cited published study has 261 citations.

83Trials tracked
62Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 25 Phase 3 37 Phase 2 12 Phase 1 3 Other / NA 6
  1. Phase 4 Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD Completed · 261 cited
  2. Phase 3 Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. Completed · 198 cited
  3. Phase 3 Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) Completed · 64 cited
  4. Phase 4 A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed · 41 cited
  5. Phase 4 A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed · 40 cited
  6. Phase 3 To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways Completed · 39 cited
Show 44 more trials
  1. Phase 3 A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Completed · 38 cited
  2. Phase 3 Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients Completed · 24 cited
  3. Phase 4 Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients Completed · 21 cited
  4. Phase 4 A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients Completed · 3 cited
  5. Phase 4 Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD Completed
  6. Phase 4 Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD Completed
  7. Phase 4 Cardiovascular Function in COPD Patients Completed
  8. Phase 4 Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients Completed
  9. Phase 4 A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed
  10. Phase 4 The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus Completed
  11. Phase 4 Phase 4 COPD and Suboptimal Inspiratory Flow Rate Completed
  12. Phase 4 Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  13. Phase 4 A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients. Completed
  14. Phase 4 A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects Completed
  15. Phase 4 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation Completed
  16. Phase 4 Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients. Completed
  17. Phase 4 Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1 Completed
  18. Phase 4 Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD) Completed
  19. Phase 4 A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). Completed
  20. Phase 4 Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease Completed
  21. Phase 4 Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients Completed
  22. Phase 4 Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2 Completed
  23. Phase 4 Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection Completed
  24. Phase 4 Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD). Completed
  25. Phase 3 Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation Completed
  26. Phase 3 Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) Completed
  27. Phase 3 Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. Completed
  28. Phase 3 Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® Completed
  29. Phase 3 Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) Completed
  30. Phase 3 The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  31. Phase 3 Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Completed
  32. Phase 3 A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control Completed
  33. Phase 3 Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Completed
  34. Phase 3 Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2) Completed
  35. Phase 3 Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Completed
  36. Phase 3 Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  37. Phase 3 Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease Completed
  38. Phase 3 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) Completed
  39. Phase 3 Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium Completed
  40. Phase 3 Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  41. Phase 3 A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Completed
  42. Phase 3 Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients Completed
  43. Phase 3 A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD Completed
  44. Phase 3 Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed

Showing the 50 most-cited and recently-updated of 83 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Montelukast vs Tiotropium Added to ICS in Children With Asthma
Allergy & Immunology RCT
Montelukast vs Tiotropium Added to ICS in Children With Asthma Asthma Treatment Comparison Shows Mixed Results for Kids
This randomized controlled trial in 152 children aged 6 to 14 years with partly controlled or uncontrolled asthma found no significant diffe…
A small trial found no clear difference between two asthma medicines for children, though one caused rare side effects.
May 1, 2026